Satsuma Pharma's migraine drug fails in late-stage study
14/11/2022 12:10
Nov 14 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O said on Monday its experimental migraine drug failed to meet the main goals of a late-stage trial. (Reporting by Manas Mishra in Bengaluru; editing by Uttaresh.V) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon